Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/CIRCULATIONAHA.114.009789 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[An ADTKD pedigree discovered from Fabry disease screening].
Zhonghua Nei Ke Za Zhi
February 2025
Department of Nephrology, Children's Hospital of Nanjing Medical University, Nanjing210008, China.
[Hypertrophic obstructive cardiomyopathy associated with Fabry disease: a case report].
Zhonghua Nei Ke Za Zhi
February 2025
Department of Cardiology, Peking University First Hospital, Beijing100034, China Institute of Cardiovascular Disease, Peking University First Hospital, Beijing100034, China Echocardiography Core Lab, Institute of Cardiovascular Disease, Peking University First Hospital, Beijing100034, China.
[Drug conversion of enzyme replacement for Fabry disease: a case report].
Zhonghua Nei Ke Za Zhi
February 2025
Department of Nephrology, Heze Municipal Hospital, Heze274000,China.
The vestibular and oculomotor dysfunction in Fabry disease: a cohort study in China.
Ann Med
December 2025
Department of Neurology, Peking University First Hospital, China.
Objective: Whereas a few studies have evaluated vestibular involvement in Fabry disease (FD), the relationship between vestibular/oculomotor abnormalities and disease-specific biomarkers remain unclear. Therefore, we seek to evaluate these quantitatively and analyze their relationship with disease phenotype and biomarkers in FD.
Methods: This cohort study enrolled 37 Chinese FD patients registered in our center.
Identification of Four New Mutations in the GLA Gene Associated with Anderson-Fabry Disease.
Int J Mol Sci
January 2025
Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy.
Anderson-Fabry disease is a hereditary, progressive, multisystemic lysosomal storage disorder caused by a functional deficiency of the enzyme α-galactosidase A (α-GalA). This defect is due to mutations in the gene, located in the long arm of the X chromosome (Xq21-22). Functional deficiency of the α-GalA enzyme leads to reduced degradation and accumulation of its substrates, predominantly globotriaosylceramide (Gb3), which accumulate in the lysosomes of numerous cell types, giving rise to the symptomatology.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!